A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Cohort Dose-Escalation Study in Patients With Chronic Kidney Disease to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of a Single Dose of COR-001 (COR-001-SC1)
Phase of Trial: Phase I
Latest Information Update: 23 Oct 2019
Price : $35 *
At a glance
- Drugs Ziltivekimab (Primary)
- Indications Renal failure
- Focus Adverse reactions
- Acronyms COR-001-SC1
- 18 Oct 2019 Status changed from recruiting to completed.
- 26 Dec 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Jan 2019.
- 15 Oct 2018 Planned End Date changed from 1 Sep 2018 to 1 Feb 2019.